Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced its management team will attend two investor conferences in April 2026: the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference. The company specializes in treatments for gastrointestinal diseases, particularly commercializing vonoprazan-based products for GERD and H. pylori infection. Webcasts of the events will be available on the company's investor relations website.
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT
Hennion & Walsh Asset Management Inc. recently purchased 114,981 shares of Phathom Pharmaceuticals (NASDAQ:PHAT) during the fourth quarter, representing a new position valued at approximately $1.91 million. This acquisition contributes to the significant institutional ownership of 99.01% for Phathom Pharmaceuticals. The company recently reported better-than-expected Q4 earnings and revenue, and analysts maintain a "Moderate Buy" rating with an average price target of $22.50.
PHAT SEC Filings - Phathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Phathom Pharmaceuticals (PHAT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events. It details various filings, such as Schedule 13G/A and 13D/A for ownership disclosures, and Form 4 for insider trading activity. Each filing is accompanied by AI-powered summaries, impact scores, and sentiment analysis to help investors quickly understand key information.
PHAT SEC Filings - Phathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Phathom Pharmaceuticals (PHAT) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports, along with insider trading forms. It features AI-powered summaries, impact scoring, and sentiment analysis for each filing to help investors quickly understand key details. Recent filings highlight Phathom's Q3 2025 financial results, clinical trial updates for VOQUEZNA, and executive compensation details.
Understanding the Setup: (PHAT) and Scalable Risk
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), highlighting strong near-term sentiment with a long-term positive bias, despite elevated downside risk due to a lack of additional long-term support signals. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis to guide investors. The piece emphasizes AI-generated signals for PHAT, providing insights into support and resistance levels across different time horizons.
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
Barclays has upgraded Phathom Pharmaceuticals (PHAT) to Overweight with an $18 price target, citing an attractive entry point despite the stock's year-to-date decline. The upgrade is based on strong prescription growth for VOQUEZNA and expectations for increased revenue and profitability by Q3 2026. The company's sole commercial asset, VOQUEZNA, is protected by New Chemical Entity exclusivity until May 2032, providing a long runway for growth.
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
This article highlights three significant analyst upgrades for Friday, March 27, 2026. JP Morgan upgraded Argan Inc. (AGX) to Overweight with a $550 price target, while Barclays upgraded Phathom Pharmaceuticals (PHAT) to Overweight, raising its price target to $18. BMO Capital also upgraded Quanta Services Inc. (PWR) to Outperform and increased its price target to $650.
Phathom Pharmaceuticals Inc (PHAT) Stock News & Articles
This article provides an overview of Phathom Pharmaceuticals Inc (PHAT), a biopharmaceutical company specializing in treatments for gastrointestinal diseases. It highlights the company's focus on vonoprazan and mentions a recent upgrade by Barclays to Overweight with an $18 price target. The page also offers current stock data for PHAT.
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays
Barclays has upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to an "overweight" rating, increasing its price target to $18, suggesting a 66.82% upside. This upgrade aligns with broadly positive analyst sentiment, as other firms like Guggenheim, Stifel, and Raymond James have also raised price targets or issued "buy" ratings for the company. Phathom Pharmaceuticals reported a slight beat on its recent quarterly earnings, and its lead asset, vonoprazan, targets gastrointestinal diseases.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages
Phathom Pharmaceuticals (NASDAQ:PHAT) has received an average "Moderate Buy" recommendation from analysts, with a 1-year average price target of $22.25. The company recently surpassed Q4 earnings expectations, reporting an EPS of ($0.08) against an expected ($0.09) and revenue of $57.58 million. Institutional investors hold a significant 99.01% of the shares in this clinical-stage biopharmaceutical company specializing in gastrointestinal treatments.
Phathom Pharmaceuticals (PHAT) director gifts 80,000 shares to trust
Phathom Pharmaceuticals director Asit Parikh gifted 80,000 shares of common stock to a trust for the benefit of his spouse on March 10, 2026. These were two separate bona fide gift transfers of 40,000 shares each, conducted with no cash consideration. Following these transactions, Parikh directly holds 10,500 shares and indirectly holds 120,500 shares through the trust where he serves as trustee.
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones
This article analyzes Phathom Pharmaceuticals Inc. (PHAT) using AI-driven quantitative research, identifying weak near and mid-term sentiment but a strong long-term positive outlook. It provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, highlighting support and resistance levels.
Certain Performance Stock Units of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.
Certain Performance Stock Units of Phathom Pharmaceuticals, Inc. are subject to a lock-up agreement, preventing executive officers, directors, and their affiliates from selling these units for 61 days, starting from January 7, 2026, and ending on March 9, 2026. This restriction is detailed in a prospectus supplement and requires the consent of Guggenheim Securities, LLC and Cantor Fitzgerald & Co. for any sales within this period.
GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT
GW&K Investment Management LLC significantly increased its stake in Phathom Pharmaceuticals (NASDAQ:PHAT) by 9.1% in Q3, now holding 1,144,330 shares valued at approximately $13.47 million. Institutional ownership of Phathom Pharmaceuticals is very high at 99.01%, with other major investors also boosting their positions. Analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $22.25.
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT
Propel Bio Management LLC reduced its stake in Phathom Pharmaceuticals (NASDAQ:PHAT) by 40.1%, selling 370,000 shares, now owning 552,927 shares valued at $6.51 million. Despite this sale, analyst sentiment towards PHAT remains cautiously optimistic with a "Moderate Buy" consensus and an average target price of $22.25. Phathom Pharmaceuticals slightly surpassed its Q3 earnings and revenue estimates and is currently trading around $11.06 with a market cap of approximately $871.5 million.
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax
Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, received 13,000 restricted stock units and 2,790 performance stock units on February 27, 2026. To cover tax withholding on these awards, he surrendered 964 shares tied to PSUs and 414 shares tied to RSUs back to the company at $12.56 per share. After these transactions, Breedlove directly holds 61,480 common shares and indirectly holds 6,945.4 shares through a 401(k) account.
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5% - Should You Sell?
Phathom Pharmaceuticals (NASDAQ:PHAT) saw its stock price drop by 6.5% on Monday, trading at $11.74 with higher-than-average volume. Despite this, MarketBeat shows a "Moderate Buy" consensus rating with an average analyst price target of $22.25. The clinical-stage biopharmaceutical company, focused on GI diseases, modestly beat quarterly EPS estimates and institutional investors hold approximately 99% of its shares.
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses
Phathom Pharmaceuticals (PHAT) saw its stock rise 13.2% after reporting narrowing losses in Q4 2025 and for the full year, and issuing 2026 guidance that projects operating profitability to begin in Q3 2026 and continue through the full year. The company expects net revenues of $320 million to $345 million in 2026, signaling a transition towards self-funded growth for its primary drug, VOQUEZNA. Despite positive guidance, the company's reliance on a single U.S.-focused asset remains a central risk.
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why
Guggenheim has increased its price target for Phathom Pharmaceuticals (PHAT) from $20 to $25, maintaining a Buy rating. This upgrade follows Phathom's strong fiscal Q4 and full-year 2025 results, which showed a significant 217% increase in FY25 net revenues and progress towards profitability in early Q3 2026. The company also strengthened its financial position through an equity offering and debt modification.
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why
Guggenheim has increased its price target for Phathom Pharmaceuticals (PHAT) to $25 from $20, maintaining a Buy rating. This adjustment follows Phathom's strong fiscal Q4 and full-year 2025 results, which included $57.6 million in Q4 net revenues and $175.1 million for the full year, a 217% increase from FY24. The firm is encouraged by Phathom's progress toward achieving profitability in early Q3 2026.
Phathom Pharmaceuticals (PHAT) Is Up 10.0% After Guiding to 2026 Operating Profitability and Raising Capital
Phathom Pharmaceuticals (PHAT) saw its stock rise 10.0% following the announcement of fourth-quarter and full-year 2025 results. The company reported significantly narrower net losses and projected operating profitability for 2026, starting in the third quarter, excluding stock-based compensation. This positive outlook is supported by a US$130 million equity raise, restructured term loans, and the continued uptake of its VOQUEZNA treatment.
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why
Guggenheim raised its price target on Phathom Pharmaceuticals (PHAT) to $25 from $20, maintaining a Buy rating. This adjustment follows Phathom's strong fiscal Q4 and full-year 2025 results, which saw net revenues grow significantly and the company aiming for profitability by early Q3 2026. The biopharmaceutical company also bolstered its financial position through an equity offering and debt modification.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals reported significant revenue growth for Q4 2025 ($57.6 million) and full year 2025 ($175.1 million), marking a 217% increase from 2024, driven by strong VOQUEZNA prescription figures. The company strengthened its financial position through a $130 million equity offering and a modified term debt, and anticipates achieving operating profitability by Q3 2026 and cash flow positivity in 2027. Phathom also provided 2026 financial guidance, projecting net revenues of $320–$345 million and non-GAAP operating expenses of $235–$255 million.
PHAT Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Phathom Pharmaceuticals, Inc. (PHAT), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's significant revenue growth of 216.9% year-over-year but also notes its unprofitability with a net income of -$221.2M and low earnings quality. The analysis points to weak financial health, a negative operating margin, and concerns about debt-servicing ability.
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS
Phathom Pharmaceuticals (NASDAQ:PHAT) surpassed Q4 earnings estimates by $0.01 per share, reporting a loss of $0.08 EPS against a consensus of ($0.09). The company also delivered strong Q4 revenue of $57.58 million and guided 2026 revenue between $320M–$345M, expecting to achieve operating profitability by Q3 2026 and cash-flow positivity in 2027. Despite an equity offering that introduced dilution risk, the company improved its capital structure and strengthened its commercial momentum in the GI market.
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating
H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Phathom Pharmaceuticals (PHAT) with a $26.00 price target. This positive outlook is driven by the early commercial success of VOQUEZNA, the significant unmet need in the GERD market, and Phathom's strengthened financial position through recent equity financing and debt renegotiations. The company's focused strategy and consistent prescription growth, coupled with a clear path to operating profitability by Q3 2026, further support the analyst's optimistic stance.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. reported strong Q4 and full-year 2025 results, exceeding revenue and expense guidance, driven by the success of VOQUEZNA. The company has enhanced its capital structure by modifying its term loan agreement, extending maturity, and reducing interest expenses, which is expected to ensure sufficient cash to meet all obligations. Phathom forecasts continued growth and anticipates achieving operational profitability by Q3 2026 and cash flow positivity in 2027, focusing on a GI-centric sales strategy and potential future asset acquisitions.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals reported strong financial results for Q4 and full year 2025, with net revenues reaching $57.6 million and $175.1 million respectively, driven by VOQUEZNA prescriptions. The company also strengthened its financial position through a $130 million equity offering and term debt modification, anticipating operating profitability in Q3 2026 and for the full year 2026. Phathom provided 2026 financial guidance projecting net revenues between $320-$345 million and non-GAAP operating expenses of $235-$250 million.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
Phathom Pharmaceuticals (PHAT) reported a narrower-than-expected Q4 loss of $0.08 per share, beating the Zacks Consensus Estimate of a $0.09 loss and significantly improving from a $0.79 loss a year ago. The company also surpassed revenue estimates, posting $57.58 million against an expected $57.42 million. Despite the positive earnings and revenue surprise, the stock has underperformed the S&P 500 year-to-date, and its current Zacks Rank of #4 (Sell) suggests potential near-term underperformance.
Heartburn drug VOQUEZNA tops 1.1M prescriptions as Phathom targets 2026 profit
Phathom Pharmaceuticals reported a significant financial increase in 2025, with net revenue jumping 217% to $175.1 million, driven by over 1.1 million VOQUEZNA prescriptions. The company completed a $130 million equity offering and modified its term debt, projecting operating profitability to begin in Q3 2026. Phathom also provided 2026 guidance, expecting net revenues between $320 million and $345 million, with a gross margin of approximately 80%.
Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative
Phathom Pharmaceuticals (PHAT) reported Q4 2025 revenue of US$57.6 million and a narrowed basic EPS loss of US$0.29, with a net loss of US$21.1 million. While revenue growth is strong, trailing 12-month net losses remain substantial at US$221.25 million, raising questions about the company's path to profitability and challenging the bullish narrative that anticipates 25.4% margins within three years. Despite the narrowing quarterly losses, the overall financial health, including negative shareholders' equity, indicates that profitability is still a significant work in progress.
Phathom Pharmaceuticals (PHAT) grows 2025 sales but remains deeply unprofitable
Phathom Pharmaceuticals (PHAT) reported strong revenue growth for Q4 and full year 2025, with net product revenue reaching $175.1 million, a 217% increase from 2024. Despite narrowing its GAAP net loss to $221.2 million, the company remains unprofitable and held $130.0 million in cash against $697.3 million in liabilities. Phathom aims for operating profitability by Q3 2026 and cash flow positivity in 2027, supported by strategic financing and expense discipline.
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 14.3% on Earnings Beat
Phathom Pharmaceuticals (NASDAQ:PHAT) saw its shares surge 14.3% in intraday trading after reporting quarterly earnings that narrowly surpassed analyst expectations. The company posted an EPS of ($0.08) against a consensus of ($0.09) and revenue of $57.58 million compared to estimates of $57.44 million. Despite the positive earnings, trading volume was significantly lower than average, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $20.71.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals reported a strong close to 2025 with $175.1 million in net revenues, a 217% increase from the previous year, driven by over 1.1 million VOQUEZNA prescriptions filled. The company also strengthened its financial position through a $130 million equity offering and modification of its term debt, expecting operating profitability to begin in Q3 2026 and for the full year 2026. Phathom provided 2026 financial guidance projecting net revenues of $320–$345 million and non-GAAP operating expenses of $235–$250 million, while also announcing ongoing clinical trials for VOQUEZNA in Eosinophilic Esophagitis.
Earnings call transcript: Phathom Pharmaceuticals Q4 2025 beats expectations, stock surges
Phathom Pharmaceuticals reported a significant beat in its Q4 2025 earnings, with an EPS of -$0.08 against an anticipated -$0.42, and revenue of $57.6 million, exceeding forecasts. The company's stock surged by 7.95% after the announcement, driven by strong growth in its Voquezna product, which has seen over 1.1 million prescriptions filled. Phathom expects to achieve operating profitability by Q3 2026 and cash flow positivity by 2027, bolstered by strategic capital structure enhancements and a refocused gastroenterology sales strategy.
Phathom Pharmaceuticals, Inc. SEC 10-K Report
Phathom Pharmaceuticals (PHAT) has released its annual 10-K report, showcasing significant financial improvements with product revenue increasing to $175.1 million and a reduced net loss of $(221.2) million, driven by the successful commercial launch of its VOQUEZNA products. The company aims for operating profitability by Q3 2026, focusing on commercialization, clinical trials for pipeline expansion, and securing additional financing, while navigating challenges like limited operating history and dependence on VOQUEZNA.
Biotech Phathom heads to Boston and Miami for investor talks in March
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that its management will participate in three investor conferences in March 2026: TD Cowen in Boston, and Jefferies Biotech on the Beach and Barclays Global Healthcare in Miami. The company will host a presentation and a fireside chat, and management will engage in one-on-one meetings. Webcasts of these events will be available on their investor relations page for 90 days.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals reported strong financial results for Q4 and full year 2025, with net revenues reaching $175.1 million, a 217% increase from 2024. The company has filled over 1.1 million VOQUEZNA prescriptions and strengthened its financial position through a $130 million equity offering and modification of term debt. Phathom anticipates achieving operating profitability by Q3 2026 and for the full year, with a projected net revenue guidance of $320–$345 million for 2026.
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections
Phathom Pharmaceuticals (PHAT) reported a narrower-than-expected loss of $0.08 per share for the fourth quarter, surpassing the consensus forecast. The company also exceeded revenue projections, generating $57.58 million, a significant increase from the previous year. Despite these positive results, Phathom's stock has declined by approximately 25.7% year-to-date, and analysts currently rank it as a "Sell" due to negative earnings estimate revisions.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, a biopharmaceutical company specializing in gastrointestinal disease treatments, announced its participation in three investor conferences in March 2026. The company's management team will attend the TD Cowen 46th Annual Health Care Conference, the Jefferies Biotech on the Beach Summit, and the Barclays 28th Annual Global Healthcare Conference, with scheduled presentations and one-on-one meetings. The events will be accessible via live webcasts and archived recordings on Phathom's investor relations website.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Rating of "Moderate Buy" from Analysts
Phathom Pharmaceuticals (NASDAQ: PHAT) has received an average "Moderate Buy" rating from nine brokerages, with an average one-year price target of $20.71. The company's stock opened at $11.42, with significant institutional ownership at 99.01%. Several institutional investors, including Frazier Life Sciences Management and 683 Capital Management, have recently increased their positions in the company.
Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday
Phathom Pharmaceuticals (PHAT) is slated to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting a loss of ($0.09) per share. The stock is currently trading down by approximately 6.9%, with significant institutional ownership at 99.01% and a "Moderate Buy" consensus rating from Wall Street analysts. The company, focused on gastrointestinal disease treatments, has an average analyst target price of $20.71.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Phathom Pharmaceuticals will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, during a live webcast at 8:00 AM EST. The biopharmaceutical company, which focuses on gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan), will also provide a business update during the event. A recording of the webcast will be available for 90 days on their investor relations website.
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit
Phathom Pharmaceuticals is shifting its commercial strategy to a primary focus on gastroenterology for its drug VOQUEZNA, aiming to achieve operating profitability in the second half of 2026. CEO Steven Basta highlighted the company's progress, including estimated 2025 revenue of $175 million and the potential for $1 billion in revenue from GI scripts alone by converting 20-30% of PPI prescriptions. The company also addressed its recent capital raise to strengthen its balance sheet and discussed plans for a potential exclusivity extension for VOQUEZNA through an eosinophilic esophagitis (EoE) program.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors, who hold a 51% stake in Phathom Pharmaceuticals (NASDAQ:PHAT), experienced an US$88 million decrease in market cap last week, despite a 110% gain over the past year. Frazier Life Sciences Management, LP is the largest shareholder with 16%, and private equity firms hold a 25% stake, influencing the company's board. The article also notes that insiders own approximately US$38 million worth of shares, indicating some alignment with other shareholders.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors hold a significant majority stake (51%) in Phathom Pharmaceuticals, Inc. While they experienced an US$88m decrease in market cap last week, their long-term gains over the past year (110%) have largely mitigated these recent losses. The article details the ownership breakdown, highlighting that a small number of institutions hold a substantial portion of the company's shares.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) experienced an US$88 million decrease in market capitalization last week, despite having seen 110% gains over the past year. Institutions hold a significant 51% stake in the company, with the top 9 shareholders collectively owning over half of the shares. While insider ownership is seen as positive, demonstrating alignment, private equity firms also hold a substantial 25% stake.
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Phathom Pharmaceuticals announced that its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 11-12, 2026, in New York, NY. The company, focused on GI disease treatments, especially vonoprazan products, will host a live webcast of the fireside chat on February 12, 2026, at 11:30 am EST. A recording will be available for 90 days on their investor relations website.
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Phathom Pharmaceuticals, Inc. announced that its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Emerging Outlook Biotech Summit 2026. The event will take place on February 11-12, 2026, in New York, NY, with the fireside chat scheduled for February 12, 2026, at 11:30 am EST. A live webcast and archived recording will be available on the company's investor relations website.
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment
Phathom Pharmaceuticals is sponsoring the 3rd Great GI Debates Conference in Fort Lauderdale, Florida, from February 6-8. The conference will serve as a platform for Phathom to showcase its pioneering GERD treatment and innovative approaches in gastroenterology. This sponsorship underscores Phathom's strategic commitment to advancing digestive health solutions.
